Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän

Protection of Kidney Func… - Göteborgs universitet Till startsida
Till innehåll Läs mer om hur kakor används på gu.se

Protection of Kidney Function with Human Antioxidation Protein α 1 -Microglobulin in a Mouse 177 Lu-DOTATATE Radiation Therapy Model

Artikel i vetenskaplig tidskrift
Författare A. Kristiansson
J. Ahlstedt
B. Holmqvist
A. Brinte
T. A. Tran
Eva Forssell-Aronsson
S. E. Strand
M. Gram
B. Akerström
Publicerad i Antioxidants and Redox Signaling
Volym 30
Nummer/häfte 14
Sidor 1746-1759
ISSN 1523-0864
Publiceringsår 2019
Publicerad vid Institutionen för kliniska vetenskaper, Avdelningen för radiofysik
Sahlgrenska Cancer Center
Sidor 1746-1759
Språk en
Länkar dx.doi.org/10.1089/ars.2018.7517
Ämnesord 177 Lu-DOTATATE, cancer, PRRT, radionuclide therapy, renal protection, α 1 -microglobulin, alpha 1 microglobulin, oxodotreotide lu 177, protective agent, animal experiment, animal model, animal tissue, apoptosis, Article, controlled study, double stranded DNA break, female, gene expression, histopathology, kidney cortex, kidney function, kidney injury, mouse, nonhuman, priority journal, proteinuria, radioisotope therapy, upregulation
Ämneskategorier Radiologi och bildbehandling


Aims: Peptide receptor radionuclide therapy (PRRT) is in clinical use today to treat metastatic neuroendocrine tumors. Infused, radiolabeled, somatostatin analog peptides target tumors that are killed by irradiation damage. The peptides, however, are also retained in kidneys due to glomerular filtration, and the administered doses must be limited to avoid kidney damage. The human radical scavenger and antioxidant, α 1 -microglobulin (A1M), has previously been shown to protect bystander tissue against irradiation damage and has pharmacokinetic and biodistribution properties similar to somatostatin analogs. In this study, we have investigated if A1M can be used as a renal protective agent in PRRT. Results: We describe nephroprotective effects of human recombinant A1M on the short- and long-term renal damage observed following lutetium 177 ( 177 Lu)-DOTATATE (150 MBq) exposure in BALB/c mice. After 1, 4, and 8 days (short term), 177 Lu-DOTATATE injections resulted in increased formation of DNA double-strand breaks in the renal cortex, upregulated expression of apoptosis and stress response-related genes, and proteinuria (albumin in urine), all of which were significantly suppressed by coadministration of A1M (7 mg/kg). After 6, 12, and 24 weeks (long term), 177 Lu-DOTATATE injections resulted in increased animal death, kidney lesions, glomerular loss, upregulation of stress genes, proteinuria, and plasma markers of reduced kidney function, all of which were suppressed by coadministration of A1M. Innovation and Conclusion: This study demonstrates that A1M effectively inhibits radiation-induced renal damage. The findings suggest that A1M may be used as a radioprotector during clinical PRRT, potentially facilitating improved tumor control and enabling more patients to receive treatment. © Amanda Kristiansson et al. 2018; Published by Mary Ann Liebert, Inc.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?